Navigation Links
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Date:2/7/2013

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012  after the NASDAQ Market closes on Thursday, February 14, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six months ended December 31, 2012 represent a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Conference call and webcast details:

Date: February 14, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 409002

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when
'/>"/>

SOURCE PHARMACYCLICS/ ACCOUNTS PAYABLE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... Caring, is a 4-Star Sponsor of Operation Grow4Vets ... with unique products, programs and services to assist them ... Key Facts: , An ever-increasing ... a safe and effective treatment for pain, Post-traumatic Stress ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET ... 7,935,528 by the United States Patent and Trademark Office (USPTO) ... cells to treat liver disease.  Under the terms of its ... worldwide exclusive licensee of U.S. patent 7,935,528.   ...
... 2011 Bacterin International Holdings, Inc. ("Bacterin") ... developer of revolutionary bone graft material and anti-infective coatings ... into an equity purchase agreement with Lincoln Park Capital ...  Under the terms of the agreement, Bacterin received an ...
Cached Medicine Technology:MultiCell Technologies is Granted Stem Cell Patent 2MultiCell Technologies is Granted Stem Cell Patent 3Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC 2Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC 3Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC 4
(Date:10/20/2014)... 2014 T.E.N., a technology and ... today that William H. Murray, renowned author and ... Luminary Leadership Award winner. Presented annually, the ISE® ... outstanding leader and industry practitioner for his or ... the information security industry. , Formerly with IBM, ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel ... for FCPX filmmakers . , “Fun, cool, and simple ... theme” Says Christina Austin, CEO of Pixel Film Studios. “It ... Citrus comes with all the tools needed for a ... for added style, a title screen for an introduction, two ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... , TUESDAY, Jan. 17 (HealthDay News) -- Retired National Football ... as sharp later in life as their counterparts who maintain ... research has found that pro football players are already at ... trauma during their on-the-field years. The new study, published ...
... cancers, in particular basal cell carcinoma, can be successfully ... The antitumor effect of imiquimod is multifactorial. One of ... its ability to modify the immune response. A team ... University of Vienna, Austria, has now identified a new ...
... can obviously save lives. But as more and stronger chemicals ... impact of all these chemicals has not kept up with ... on how chemicals in our drugs and also in the ... some of the most important cells in our body: stem ...
... 2012. Neuroscientists at Kessler Foundation have documented increased ... following memory retraining using the modified Story Memory ... demonstrate that behavioral interventions can have a positive ... step in validating the clinical utility of cognitive ...
... Reporter , TUESDAY, Jan. 17 (HealthDay News) -- They may ... tobacco products aren,t for kids. The safety and risks ... and Drug Administration meeting this week. "Dissolvables" are ... are not stop-smoking aids. Instead, they are designed to allow ...
... Centro de Genmica e Investigacin Oncolgica (GENYO) of which ... Government are members have identified the genetic and phenotypic ... of metastasis -which is the main cause of cancer ... with no direct anatomical relationship with the organ originally ...
Cached Medicine News:Health News:Heavier Ex-NFL Players May Be Prone to Brain Decline 2Health News:Heavier Ex-NFL Players May Be Prone to Brain Decline 3Health News:Researchers study how chemicals in drugs and around us impact stem cells 2Health News:Researchers study how chemicals in drugs and around us impact stem cells 3Health News:FDA to Weigh Safety of Tobacco Lozenges, Strips 2Health News:FDA to Weigh Safety of Tobacco Lozenges, Strips 3Health News:University of Granada researchers identify changes in tumor cells that lead to metastasis 2
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
... highly sensitive DR system. It features a ... is designed for most general radiographic applications. ... wall stand and table configurations. , ... produces detailed patient images with reduced dose. ...
... ulitizes ultrasonic waves to remove bone cement speedily ... probe liquifies the cement at the point of ... , ,A special feature of the apparatus is ... to signal this to the operator instantly. Probe ...
Provides stable positioning of the knee during surgery....
Medicine Products: